Nashik: The city recorded a marginal rise in dengue cases between Jan 1 and 21, compared to the cases reported in Dec last year.
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its ...
Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.
The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.
Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.
Indian badminton player HS Prannoy is overcoming challenging setbacks, including health issues, to make a comeback.
A few weeks after the Olympics, Prannoy announced on social media that he would like to withdraw from the upcoming ...
As cases of dengue fever skyrocketed globally this past year, new findings by Stanford researchers and their international ...
Male insects carrying venom proteins transferred these to disease-spreading females, reducing their lifespan and providing a ...